NextCell Pharma AB (NXTCL) — Cash Flow-to-Debt Ratio
Latest as of August 2025:
-1.04x
NextCell Pharma AB (NXTCL) has a Cash Flow-to-Debt Ratio of -1.04x as of August 2025, meaning its operating cash flow of Skr-10.77 Million could theoretically repay -1% of its total liabilities (Skr10.34 Million) in one year. See financial agility of NextCell Pharma AB to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
-1.04x
Operating CF / Total Liabilities
Operating Cash Flow
Skr-10.77 Million
SEK
Total Liabilities
Skr10.34 Million
SEK
Data as of
Aug 2025
Most recent filing
NextCell Pharma AB Cash Flow-to-Debt Ratio (2015–2025)
Historical debt coverage capacity for NextCell Pharma AB across 11 annual periods. For the full cash flow conversion analysis, see NextCell Pharma AB cash flow conversion.
Annual Cash Flow-to-Debt Ratio for NextCell Pharma AB (2015–2025)
Year-by-year debt coverage analysis for NextCell Pharma AB.
| Year | CF-to-Debt Ratio | Operating CF (SEK) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -3.76x | Skr-38.86 Million | Skr10.34 Million | ▼ -36.1% |
| 2024 | -2.76x | Skr-37.78 Million | Skr13.69 Million | ▲ +17.5% |
| 2023 | -3.35x | Skr-43.83 Million | Skr13.10 Million | ▲ +8.4% |
| 2022 | -3.65x | Skr-33.31 Million | Skr9.12 Million | ▲ +20.9% |
| 2021 | -4.62x | Skr-25.58 Million | Skr5.53 Million | ▲ +13.3% |
| 2020 | -5.33x | Skr-18.96 Million | Skr3.56 Million | ▲ +9.5% |
| 2019 | -5.89x | Skr-22.13 Million | Skr3.76 Million | ▼ -50.8% |
| 2018 | -3.91x | Skr-13.55 Million | Skr3.47 Million | ▲ +32.7% |
| 2017 | -5.80x | Skr-14.82 Million | Skr2.55 Million | ▼ -41.0% |
| 2016 | -4.12x | Skr-11.12 Million | Skr2.70 Million | ▼ -37.2% |
| 2015 | -3.00x | Skr-7.76 Million | Skr2.59 Million | — |
Cash Flow-to-Debt Ratio = Operating Cash Flow / Total Liabilities. Higher is better for debt service capacity.